Baird Medical Investment Holdings Ltd

Aktienanalyse zu Baird Medical Investment Holdings Ltd (BDMD)

$1.100

0.000 (0.00%)Zum Schluss

Loading chart…
High
1.132
Open
1.060
VWAP
1.10
Vol
33.51K
Mkt Cap
Low
1.060
Amount
36.76K
EV/EBITDA, TTM
-0.00

Baird Medical Investment Holdings Ltd is a holding company primarily engaged in the research and development, manufacture and sales of microwave ablation (MWA) medical devices. The Company’s MWA medical devices primarily include MWA needles and MWA therapeutic apparatus. The Company is also engaged in the sales of other medical devices, including catheters, ventilators, operation tables, medical gloves, syringes and other large medical machines and systems. The proprietary medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. The Company primarily conducts its businesses in the domestic market.

AI analysis of Baird Medical Investment Holdings Ltd (BDMD)

hold

Baird Medical Investment Holdings Ltd is currently not a strong buy due to its recent financial performance and technical indicators. The stock has a current price of $1.12, and the RSI is at 41.197, indicating it is nearing oversold territory but not yet a clear buy signal. Additionally, the forward P/E ratio is 11.49, which is reasonable, but the company reported a significant decline in revenue with a 52.74% drop over the past year, raising concerns about its profitability. The main risk is the projected EPS of -0.98 for FY 2025, indicating ongoing financial challenges.

Bewertungskennzahlen

The current forward P/E ratio for Baird Medical Investment Holdings Ltd (BDMD) is 11.49, compared to its 5-year average forward P/E of 0.23.

Forward P/E

Strongly Overvalued
5Y Average P/E
0.23
Current P/E
11.49
Überbewertet
1.83
Unterbewertet
-1.38

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-0.00
Current EV/EBITDA
-0.00
Überbewertet
0.00
Unterbewertet
-0.00

Forward P/S

Strongly Overvalued
5Y Average P/S
0.00
Current P/S
0.00
Überbewertet
0.00
Unterbewertet
-0.00

Alphio AI Price Scenarios for BDMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BDMD

$3.34

Szenariopreis

B

Base

Base · 50%BDMD

$2.78

Szenariopreis

B

Bear

Bear · 25%BDMD

$2.49

Szenariopreis

Event-Zeitleiste

2026-08-20 (ET)

09:30:00

Baird Medical Receives Product Registrations in Pakistan

2026-08-10 (ET)

09:00:00

Baird Medical and Tianjin Yuanshan Medical Sign Strategic Cooperation Agreement

2026-05-22 (ET)

09:10:00

Baird Medical Files $50M Mixed Securities Shelf

2026-03-16 (ET)

08:40:00

Baird Medical Successfully Holds Clinical Training Workshops in Indonesia

2026-01-26 (ET)

08:50:00

Baird Medical Forms Strategic Partnership with Stonewood Key Capital

News

BDMD FAQ — answered by Alphio AI

Baird Medical Investment Holdings Ltd is a holding company primarily engaged in the research and development, manufacture and sales of microwave ablation (MWA) medical devices. The Company’s MWA medical devices primarily include MWA needles and MWA therapeutic apparatus. The Company is also engaged in the sales of other medical devices, including catheters, ventilators, operation tables, medical gloves, syringes and other large medical machines and systems. The proprietary medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. The Company primarily conducts its businesses in the domestic market. It operates in the Healthcare sector.

Baird Medical Investment Holdings Ltd is currently not a strong buy due to its recent financial performance and technical indicators. The stock has a current price of $1.12, and the RSI is at 41.197, indicating it is nearing oversold territory but not yet a clear buy signal. Additionally, the forward P/E ratio is 11.49, which is reasonable, but the company reported a significant decline in revenue with a 52.74% drop over the past year, raising concerns about its profitability. The main risk is the projected EPS of -0.98 for FY 2025, indicating ongoing financial challenges.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten